Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Photodynamic Therapy for Cancer: What's Past is Prologue.

Literature DB >> 31820824

Photodynamic Therapy for Cancer: What's Past is Prologue.

Abstract

Thomas J Dougherty from Roswell Park Cancer Center played a major role in the progress of photodynamic therapy (PDT) from a laboratory science into a real-world clinical therapy to treat patients with cancer. Nevertheless over the succeeding 45 years, it is fair to say that the overall progress of clinical PDT for cancer has been somewhat disappointing. The goal of this perspective article is to summarize some of the clinical trials run by various companies using photosensitizers with different structures that have been conducted for different types of cancer. While some have been successful, others have failed, and several are now ongoing. I will attempt to touch on some factors, which have influenced this checkered history and look forward to the future of clinical PDT for cancer.

Entities: Chemical Disease Gene Species

Mesh：

Substances：
Photosensitizing Agents

Year: 2020 PMID： 31820824 PMCID： PMC7282978 DOI： 10.1111/php.13190

Source DB: PubMed Journal: Photochem Photobiol ISSN： 0031-8655 Impact factor: 3.421

72 in total

1. Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.

Authors: Jarod C Finlay; Timothy C Zhu; Andreea Dimofte; Diana Stripp; S Bruce Malkowicz; Theresa M Busch; Stephen M Hahn
Journal: Photochem Photobiol Date: 2006 Sep-Oct Impact factor: 3.421

2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

Authors:
Journal: Arch Ophthalmol Date: 1999-10

3. Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin).

Authors: S I Moriwaki; J Misawa; Y Yoshinari; I Yamada; M Takigawa; Y Tokura
Journal: Photodermatol Photoimmunol Photomed Date: 2001-10 Impact factor: 3.135

4. HPD - a study of its components and their properties.

Authors: R Bonnett; M C Berenbaum
Journal: Adv Exp Med Biol Date: 1983 Impact factor: 2.622

5. Photobiological properties of phthalocyanine photosensitizers Photosens, Holosens and Phthalosens: A comparative in vitro analysis.

Authors: Anna A Brilkina; Lubov V Dubasova; Ekaterina A Sergeeva; Anton J Pospelov; Natalia Y Shilyagina; Natalia M Shakhova; Irina V Balalaeva
Journal: J Photochem Photobiol B Date: 2018-12-27 Impact factor: 6.252

6. New halogenated water-soluble chlorin and bacteriochlorin as photostable PDT sensitizers: synthesis, spectroscopy, photophysics, and in vitro photosensitizing efficacy.

Authors: Janusz M Dabrowski; Luis G Arnaut; Mariette M Pereira; Carlos J P Monteiro; Krystyna Urbańska; Sérgio Simões; Grazyna Stochel
Journal: ChemMedChem Date: 2010-10-04 Impact factor: 3.466

7. The synthesis, photophysical and photobiological properties and in vitro structure-activity relationships of a set of silicon phthalocyanine PDT photosensitizers.

Authors: J He; H E Larkin; Y S Li; D Rihter; S I Zaidi; M A Rodgers; H Mukhtar; M E Kenney; N L Oleinick
Journal: Photochem Photobiol Date: 1997-03 Impact factor: 3.421

8. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.

Authors: Hiral Patel; Rosemarie Mick; Jarod Finlay; Timothy C Zhu; Elizabeth Rickter; Keith A Cengel; S Bruce Malkowicz; Stephen M Hahn; Theresa M Busch
Journal: Clin Cancer Res Date: 2008-08-01 Impact factor: 12.531

Review 9. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies.

Authors: Janine D Miller; Elma D Baron; Heather Scull; Andrew Hsia; Jeffrey C Berlin; Thomas McCormick; Valdir Colussi; Malcolm E Kenney; Kevin D Cooper; Nancy L Oleinick
Journal: Toxicol Appl Pharmacol Date: 2007-02-15 Impact factor: 4.219

10. Hemodynamic effect of the metallopurpurin SnET2 and light on transplantable FANFT induced bladder tumor.

Authors: S H Selman; B S Qin; H R James; R W Keck; G M Garbo; A R Morgan
Journal: J Urol Date: 1990-03 Impact factor: 7.450

26 in total

1. Ruthenium Photosensitizers for NIR PDT Require Lowest-Lying Triplet Intraligand (³IL) Excited States.

Authors: Liubov M Lifshits; John A Roque; Elamparuthi Ramasamy; Randolph P Thummel; Colin G Cameron; Sherri A McFarland
Journal: J Photochem Photobiol Date: 2021-09-15

Review 2. Which cell death modality wins the contest for photodynamic therapy of cancer?

Authors: Maria Vedunova; Dmitri V Krysko; Tatiana Mishchenko; Irina Balalaeva; Anastasia Gorokhova
Journal: Cell Death Dis Date: 2022-05-13 Impact factor: 9.685

3. The Endogenous Tryptophan-derived Photoproduct 6-formylindolo[3,2-b]carbazole (FICZ) is a Nanomolar Photosensitizer that Can be Harnessed for the Photodynamic Elimination of Skin Cancer Cells in Vitro and in Vivo.

Authors: Rebecca Justiniano; Lohanna de Faria Lopes; Jessica Perer; Anh Hua; Sophia L Park; Jana Jandova; Maurício S Baptista; Georg T Wondrak
Journal: Photochem Photobiol Date: 2020-09-14 Impact factor: 3.421

Photodynamic Therapy for Cancer: What's Past is Prologue.

1. Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.

2. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.

3. Analysis of photosensitivity in Japanese cancer-bearing patients receiving photodynamic therapy with porfimer sodium (Photofrin).

4. HPD - a study of its components and their properties.

5. Photobiological properties of phthalocyanine photosensitizers Photosens, Holosens and Phthalosens: A comparative in vitro analysis.

6. New halogenated water-soluble chlorin and bacteriochlorin as photostable PDT sensitizers: synthesis, spectroscopy, photophysics, and in vitro photosensitizing efficacy.

7. The synthesis, photophysical and photobiological properties and in vitro structure-activity relationships of a set of silicon phthalocyanine PDT photosensitizers.

8. Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.

Review 9. Photodynamic therapy with the phthalocyanine photosensitizer Pc 4: the case experience with preclinical mechanistic and early clinical-translational studies.

10. Hemodynamic effect of the metallopurpurin SnET2 and light on transplantable FANFT induced bladder tumor.

1. Ruthenium Photosensitizers for NIR PDT Require Lowest-Lying Triplet Intraligand (³IL) Excited States.

Review 2. Which cell death modality wins the contest for photodynamic therapy of cancer?

3. The Endogenous Tryptophan-derived Photoproduct 6-formylindolo[3,2-b]carbazole (FICZ) is a Nanomolar Photosensitizer that Can be Harnessed for the Photodynamic Elimination of Skin Cancer Cells in Vitro and in Vivo.

4. Peripherally Crowded Cationic Phthalocyanines as Efficient Photosensitizers for Photodynamic Therapy.

Review 5. Factors Determining the Susceptibility of Bacteria to Antibacterial Photodynamic Inactivation.

6. Oxidative Damage Induced by Phototoxic Pheophorbide a 17-Diethylene Glycol Ester Encapsulated in PLGA Nanoparticles.

Review 7. Developments in Vascular-Targeted Photodynamic Therapy for Urologic Malignancies.

Review 8. Autophagy Regulation and Photodynamic Therapy: Insights to Improve Outcomes of Cancer Treatment.

9. NIR-Absorbing Ru^II Complexes Containing α-Oligothiophenes for Applications in Photodynamic Therapy.

Review 10. Clinical development and potential of photothermal and photodynamic therapies for cancer.